上海中藥創(chuàng)新研究中心

400-6699-117轉(zhuǎn)1000

      上海中藥創(chuàng)新研究中心(以下簡(jiǎn)稱“中心”)是在中國(guó)科技部和上海市人民政府的支持下，于 2000 年 4 月由上海市科委、上海市浦東新區(qū)政府和上海市張江高科技園區(qū)開(kāi)發(fā)公司共同投資組建的中藥現(xiàn)代化研究和開(kāi)發(fā)機(jī)構(gòu)，是國(guó)家中藥現(xiàn)代化(上海)創(chuàng)新中心的依托單位，是國(guó)家生物醫(yī)藥基地重點(diǎn)建設(shè)的國(guó)家級(jí)專業(yè)孵化器之一，也是國(guó)家國(guó)際科技合作基地和上海市研究生聯(lián)合培養(yǎng)基地。

      Shanghai Innovative Research Center of Traditional Chinese Medicine (SIRC/TCM), as a research and development (R&D) institution for TCM modernization, was co-founded by Science and Technology Committee of Shanghai, Pudong New Area Government of Shanghai and Shanghai Zhangjiang Hi-Tech Park Development Corporation in April 2000. With supports from Ministry of Science and Technology of China and Shanghai Municipal Government, SIRC/TCM is designated as a core Innovation Center of TCM Modernization in Shanghai, a national key incubator for biomedical research in China, an international science and technology cooperation base in China, and a post-graduation co-education base in Shanghai.

      作為國(guó)家級(jí)專業(yè)科研機(jī)構(gòu)，中心以“市場(chǎng)為導(dǎo)向，創(chuàng)新為手段”，遵循“源于中藥、高于中藥”的研發(fā)理念，開(kāi)創(chuàng)性地進(jìn)行中藥新藥的探索研究，并獨(dú)立創(chuàng)建了中藥現(xiàn)代化的兩大創(chuàng)新研究體系：

1）世界一流的大型綜合性關(guān)聯(lián)型中藥數(shù)據(jù)庫(kù)；

2）吸收/代謝后單體組合藥物(PAMD)創(chuàng)新理念及其實(shí)驗(yàn)方法。

      中藥數(shù)據(jù)庫(kù)囊括了三萬(wàn)多個(gè)中草藥中天然含有的活性化合物及其他信息，涉及分子結(jié)構(gòu)、生物活性、化合物來(lái)源(草藥)、毒性、中藥方劑以及臨床應(yīng)用等。中藥數(shù)據(jù)庫(kù)已廣泛應(yīng)用于篩選先導(dǎo)化合物、研究中藥作用機(jī)理、預(yù)見(jiàn)草藥方劑毒性以及開(kāi)發(fā)全新中藥復(fù)方等。

      As a national R&D center, SIRC/TCM is innovation-oriented and market-guided with the mission of developing novel drugs that are “from TCM, better than TCM”. Our approach of TCM modernization is based on two innovations generated by SIRC scientists: 1) a world-class comprehensive and interactive TCM database; 2) a novel concept of Post-Absorption and Metabolism Drugs (PAMD). The TCM database contains information about more than 30,000 compounds that are active ingredients of TCM herbs. The interactive structure of this database provides information of these compounds in a range of molecular structure, biological activity, herbs containing those compounds, toxicity, as well as TCM formula and their clinical application. The database has been widely used in screening for lead compounds, studying mechanisms of TCM drugs, predicting toxicity of herbal combinations, as well as creating new TCM formulas.

      PAMD研究理念旨在從口服草藥后存留于體內(nèi)的化合物中探尋新藥，而且這些草藥的臨床療效確切，安全性穩(wěn)定、可靠。因?yàn)槿梭w吸收的化合物數(shù)量不足中藥方劑所含化合物的1%，而且其中大量化合物是原有活性成分的代謝物，所以運(yùn)用PAMD策略可以極大地提高從中藥中探索先導(dǎo)化合物的效率，以研發(fā)新的單體化合物藥物以及來(lái)自中藥復(fù)方的組合化合物藥物。中心已經(jīng)成功研發(fā)了一系列擁有自主知識(shí)產(chǎn)權(quán)的新藥，其中多個(gè)新藥即將進(jìn)入臨床研究甚至已經(jīng)上市。

      The concept of PAMD is to seek drug candidates among compounds existing in our body after orally taking TCM herbs, of which are with proven clinical benefits and demonstrated safety profiles. Given the fact that compounds absorbed by our body is less than 1% of those contained in TCM formula and many of them are metabolites of original active ingredients, PAMD strategy drastically improved efficiency in finding lead compounds from TCM for development of new single compound drugs as well as compound-combinations derived from TCM formulas. With the PAMD strategy, a series of proprietary drug candidates and products have been developed and some of them are near clinical stage or already on the market.

      中心的研發(fā)技術(shù)平臺(tái)融合中藥數(shù)據(jù)庫(kù)、植物化學(xué)、分析技術(shù)、有機(jī)合成、分子藥理學(xué)、細(xì)胞生物學(xué)、毒理、中藥基因組、轉(zhuǎn)錄組學(xué)、代謝組學(xué)、藥效動(dòng)力學(xué)、計(jì)算機(jī)輔助藥物設(shè)計(jì)、公斤級(jí)化學(xué)合成等多個(gè)學(xué)科。我們與國(guó)內(nèi)外科學(xué)家和制藥廠商保持廣泛密切的聯(lián)系和合作。我們深信，中藥作為中國(guó)幾千年臨床應(yīng)用實(shí)踐證明了的無(wú)價(jià)瑰寶，若能融合創(chuàng)新研發(fā)理念和先進(jìn)實(shí)驗(yàn)技術(shù)，那么古老而神秘的中藥必將引入現(xiàn)代醫(yī)學(xué)殿堂，為現(xiàn)代藥物研發(fā)帶來(lái)劃時(shí)代的變革。

      Research at SIRC/TCM employs a broad technological platform that integrates TCM informatics, phytochemistry, analytical technology, organic synthesis, molecular pharmacology, cell biology, toxicology, TCM genomics, transcriptomics, metabolomics, pharmacokinetics, computer-aid drug design and kilogram-scale chemical synthesis. We are well-connected with national and international scientists and pharmaceutical industries. People at SIRC/TCM believe that TCM is priceless treasure generated by Chinese people through clinical practice in past thousands of years and that innovative concepts with integrative technologies will eventually bring the ancient TCM to the modern medical sciences and revolutionize our approach in drug discovery as well as development of the modern pharmaceutical industry.